Progressive supranuclear palsy: clinical and genetic aspects

Area of Science:

• Neurology
• Genetics
• Biochemistry

Background:

• Progressive supranuclear palsy (PSP) is a neurodegenerative disease with characteristic clinical features.
• Epidemiological studies indicate PSP may be more prevalent than previously thought and often misdiagnosed.
• Understanding the genetic and clinical aspects of PSP is crucial for improved diagnosis and treatment.

Purpose of the Study:

• To review recent literature on the clinical and genetic facets of progressive supranuclear palsy.
• To synthesize new findings regarding diagnostic tools and underlying pathology.
• To identify current challenges and future directions in PSP research.

Main Methods:

• Review of recent clinical studies and clinicopathological correlations.
• Analysis of epidemiological data on PSP prevalence and misdiagnosis rates.
• Examination of findings from novel laboratory and imaging techniques, including cerebrospinal fluid tau protein levels.
• Evaluation of pathological and biochemical studies on PSP brains focusing on tau protein isoforms.

Main Results:

• Clinical features of PSP are well-defined, but the disorder is frequently misdiagnosed.
• Cerebrospinal fluid tau protein levels show promise as a diagnostic aid.
• Pathological studies reveal predominant hyperphosphorylated tau isoforms (4R) in PSP brains.
• Genetic studies show an association between PSP and tau gene polymorphisms, but a specific risk allele is not identified.
• Familial tauopathies with overlap to sporadic PSP have been described.

Conclusions:

• Recent studies enhance the delineation of PSP clinical features, aiding earlier and more accurate premortem diagnosis.
• Despite advances, the lack of specific biomarkers remains a challenge for early diagnosis.
• The precise cause of PSP remains unknown, although biochemical studies offer potential for better characterization.